228 related articles for article (PubMed ID: 37576902)
1. WR1065 conjugated to thiol-PEG polymers as novel anticancer prodrugs: broad spectrum efficacy, synergism, and drug resistance reversal.
Walker DM; Lazarova TI; Riesinger SW; Poirier MC; Messier T; Cunniff B; Walker VE
Front Oncol; 2023; 13():1212604. PubMed ID: 37576902
[TBL] [Abstract][Full Text] [Related]
2. Cytostatic activity of cisplatin in the presence of WR2721 and its thiol metabolite WR1065 in OVCAR-3 human ovarian cancer cells as compared to V79 fibroblasts.
Treskes M; Nijtmans L; Fichtinger-Schepman AM; van der Vijgh WJ
Anticancer Res; 1992; 12(6B):2261-5. PubMed ID: 1338281
[TBL] [Abstract][Full Text] [Related]
3. The cytoprotective aminothiol WR1065 activates p21waf-1 and down regulates cell cycle progression through a p53-dependent pathway.
North S; El-Ghissassi F; Pluquet O; Verhaegh G; Hainaut P
Oncogene; 2000 Feb; 19(9):1206-14. PubMed ID: 10713709
[TBL] [Abstract][Full Text] [Related]
4. Maintenance of manganese superoxide dismutase (SOD2)-mediated delayed radioprotection induced by repeated administration of the free thiol form of amifostine.
Murley JS; Nantajit D; Baker KL; Kataoka Y; Li JJ; Grdina DJ
Radiat Res; 2008 May; 169(5):495-505. PubMed ID: 18439041
[TBL] [Abstract][Full Text] [Related]
5. Antiretroviral activity of the aminothiol WR1065 against Human Immunodeficiency virus (HIV-1) in vitro and Simian Immunodeficiency virus (SIV) ex vivo.
Poirier MC; Olivero OA; Hardy AW; Franchini G; Borojerdi JP; Walker VE; Walker DM; Shearer GM
AIDS Res Ther; 2009 Nov; 6():24. PubMed ID: 19895691
[TBL] [Abstract][Full Text] [Related]
6. Delayed radioprotection by nuclear transcription factor kappaB -mediated induction of manganese superoxide dismutase in human microvascular endothelial cells after exposure to the free radical scavenger WR1065.
Murley JS; Kataoka Y; Weydert CJ; Oberley LW; Grdina DJ
Free Radic Biol Med; 2006 Mar; 40(6):1004-16. PubMed ID: 16540396
[TBL] [Abstract][Full Text] [Related]
7. Enhanced Sensitivity of Nonsmall Cell Lung Cancer with Acquired Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors to Phenformin: The Roles of a Metabolic Shift to Oxidative Phosphorylation and Redox Balance.
Kim S; Im JH; Kim WK; Choi YJ; Lee JY; Kim SK; Kim SJ; Kwon SW; Kang KW
Oxid Med Cell Longev; 2021; 2021():5428364. PubMed ID: 34367462
[TBL] [Abstract][Full Text] [Related]
8. Restoration of wild-type conformation and activity of a temperature-sensitive mutant of p53 (p53(V272M)) by the cytoprotective aminothiol WR1065 in the esophageal cancer cell line TE-1.
North S; Pluquet O; Maurici D; El-Ghissassi F; Hainaut P
Mol Carcinog; 2002 Mar; 33(3):181-8. PubMed ID: 11870884
[TBL] [Abstract][Full Text] [Related]
9. p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma.
Giordano F; Vaira V; Cortinovis D; Bonomo S; Goedmakers J; Brena F; Cialdella A; Ianzano L; Forno I; Cerrito MG; Giovannoni R; Ferri GL; Tasciotti E; Vicent S; Damarco F; Bosari S; Lavitrano M; Grassilli E
J Exp Clin Cancer Res; 2019 Jun; 38(1):260. PubMed ID: 31200752
[TBL] [Abstract][Full Text] [Related]
10. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
[TBL] [Abstract][Full Text] [Related]
11. Clinical pharmacokinetics of amifostine and WR1065 in pediatric patients with medulloblastoma.
McKibbin T; Panetta JC; Fouladi M; Gajjar A; Bai F; Okcu MF; Stewart CF
Clin Cancer Res; 2010 Feb; 16(3):1049-57. PubMed ID: 20103669
[TBL] [Abstract][Full Text] [Related]
12. In vitro protection from cisplatin-induced neurotoxicity by amifostine and its metabolite WR1065.
Verstappen CC; Geldof AA; Postma TJ; Heimans JJ
J Neurooncol; 1999 Aug; 44(1):1-5. PubMed ID: 10582662
[TBL] [Abstract][Full Text] [Related]
13. Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death.
Chen P; Huang HP; Wang Y; Jin J; Long WG; Chen K; Zhao XH; Chen CG; Li J
J Exp Clin Cancer Res; 2019 Jun; 38(1):254. PubMed ID: 31196210
[TBL] [Abstract][Full Text] [Related]
14. Relationship between phosphorylated histone H2AX formation and cell survival in human microvascular endothelial cells (HMEC) as a function of ionizing radiation exposure in the presence or absence of thiol-containing drugs.
Kataoka Y; Murley JS; Baker KL; Grdina DJ
Radiat Res; 2007 Jul; 168(1):106-14. PubMed ID: 17723002
[TBL] [Abstract][Full Text] [Related]
15. Combined epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor and chemotherapy in non-small-cell lung cancer: chemo-refractoriness of cells harboring sensitizing-EGFR mutations in the presence of gefitinib.
Tsai CM; Chen JT; Chiu CH; Lai CL; Hsiao SY; Chang KT
Lung Cancer; 2013 Nov; 82(2):305-12. PubMed ID: 24055492
[TBL] [Abstract][Full Text] [Related]
16. Differential activation of nuclear transcription factor kappaB, gene expression, and proteins by amifostine's free thiol in human microvascular endothelial and glioma cells.
Grdina DJ; Murley JS; Kataoka Y; Calvin DP
Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):103-11. PubMed ID: 11917294
[TBL] [Abstract][Full Text] [Related]
17. Aminothiol WR1065 induces differential gene expression in the presence of wild-type p53.
Mann K; Hainaut P
Oncogene; 2005 Jun; 24(24):3964-75. PubMed ID: 15750621
[TBL] [Abstract][Full Text] [Related]
18. Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer.
Huang Q; Wang Q; Li D; Wei X; Jia Y; Zhang Z; Ai B; Cao X; Guo T; Liao Y
J Exp Clin Cancer Res; 2019 Mar; 38(1):129. PubMed ID: 30876460
[TBL] [Abstract][Full Text] [Related]
19. New liquid chromatographic assay with electrochemical detection for the measurement of amifostine and WR1065.
Bai F; Kirstein MN; Hanna SK; Stewart CF
J Chromatogr B Analyt Technol Biomed Life Sci; 2002 Jun; 772(2):257-65. PubMed ID: 12007770
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of high-dose pulsatile gefitinib in non-small-cell lung cancer with acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors.
Wan Y; Yuan Y; Pan Y; Zhang Y
Exp Ther Med; 2017 Jun; 13(6):3067-3074. PubMed ID: 28587381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
